UK FSA Calls for Views on New Martek Algal Oil
Martek has now developed an improved strain of this microalgae that produces an oil rich in both DHA and eicosapentaenoic acid (EPA). These are both omega-3 fatty acids. The DHA and EPA-rich oil is known as DHA-O.
Oct 27 2011 --- An independent committee of scientists appointed by the FSA has considered an application from Martek Biosciences Corporation (now part of DSM) for approval to market oil that is produced from Schizochytrium microalgae, as a novel food ingredient. Views are wanted on the expert committee’s draft opinion.
A novel food is a food or food ingredient that does not have a significant history of consumption within the European Union before 15 May 1997. Before any new food product can be introduced on the European market, it must be assessed rigorously for safety. In the UK, the assessment of novel food is carried out by the Advisory Committee on Novel Foods and Processes (ACNFP).
Martek Biosciences Corporation, has previously gained approval to use docosahaexanoic acid (DHA)-rich oil, produced from Schizochytrium, as a novel food ingredient. Martek has now developed an improved strain of this microalgae that produces an oil rich in both DHA and eicosapentaenoic acid (EPA). These are both omega-3 fatty acids. The DHA and EPA-rich oil is known as DHA-O.
Martek intends to market DHA-O at similar use levels and in similar food categories to those currently approved for its DHA-rich oil. These food categories include food supplements, bakery products, and breakfast cereals. Approval for uses in biscuits (cookies) and cooking oils is also sought.
Martek Biosciences Corporation applied for the authorisation of DHA and EPA-rich algal oil (DHA-O) under the Novel Food Regulation (EC) 258/97 in April 2011.
